Ethics & Compliance Switzerland, in cooperation with Ethixbase360, have the pleasure to invite you to the following event.

Managing Human Rights and Corruption Risks Across Life Sciences Third Parties

Date /Time: April 15th at 14:00 – 15:00 pm CET

Format: webinar

Registration is closed.

Life sciences companies face intensifying regulatory scrutiny over how human rights risks are governed across global third-party ecosystems. From clinical research organizations and trial sites to distributors, manufacturers, and logistics partners, regulators increasingly expect organizations to demonstrate effective oversight of modern slavery, labor practices, ethical sourcing, and related corruption risks—particularly where operations extend into high-risk jurisdictions.

This webinar will explore how organizations can adapt their third-party due diligence and monitoring programs in response to expanding human rights and supply-chain regulations, including emerging mandatory due diligence requirements such as the EU’s Corporate Sustainability Due Diligence Directive (CSDDD) and related frameworks. Using examples from the life sciences sector, the discussion will focus on practical ways to identify, prioritize, and manage human rights risks across complex third-party networks while keeping programs proportionate and consistent.

Panelists will explore how organizations can align anti-bribery and corruption controls with human rights obligations, respond to expanding mandatory due diligence regimes, and ensure governance frameworks withstand regulatory, investor, and public scrutiny.

Key discussion areas include:

• Identifying and prioritizing human rights risks across life sciences third parties, including clinical trial partners, distributors, manufacturers, and supply-chain intermediaries
• Adapting third-party due diligence processes to meet emerging human rights and supply-chain requirements, including CSDDD, Swiss, and UK frameworks
• Integrating human rights considerations into existing anti-bribery, corruption, and sanctions risk assessments to avoid siloed programs
• Designing proportionate, risk-based monitoring and escalation approaches that remain effective as third-party ecosystems grow and regulations evolve

Peter Nestor

Peter is the Head of Human Rights at Novartis, responsible for overseeing the company’s development and implementation of human rights requirements, aligned with the UN Guiding Principles on Business & Human Rights and emerging legal standards.

Peter joined Novartis in 2019, after serving as the Director of Human Rights at BSR, a non-profit organization advising companies across industries on human rights. Peter currently serves as the Vice-Chair on the Board of the Pharmaceutical Supply Chain Initiative (PSCI), and previously as the Co-Chair of the PSCI Human Rights and Labor Subcommittee, where he led several collective action projects and human rights training workshops for pharmaceutical companies.

Peter is a founding member of the Healthcare and Human Rights Forum, a collaboration between pharmaceutical companies established in 2023 to address a range of human rights issues outside the supply chain.

James Swenson leads Ethixbase360’s Enhanced Due Diligence (EDD) business from London and brings over 20 years of experience helping global multinationals design, implement, and strengthen third-party risk management programs. He specializes in navigating complex regulatory environments and is widely recognized for his work in AML, counter-terrorism financing, anti-bribery and corruption risk assessments, and politically exposed person (PEP) screening, delivering practical due diligence solutions aligned with regulatory expectations. He holds an MBA from The City University of London Business School in London and an undergraduate degree from the University of Virginia.